Resilience Fund: Strand 2 to support Health and Lifesciences II Project -103944

创伤是尚未得到满足的主要临床需求，也是全世界年轻人死亡和致残的主要原因。创伤治疗和管理是非常复杂、昂贵和资源密集型的。这是一个快速变化的环境，临床医生不断寻求最佳治疗来管理和稳定病情严重的患者。在这些患者中，失血会导致凝血因子的正常水平紊乱，从而导致凝血障碍。这种有缺陷的凝血过程会导致持续失控的出血，这有很高的死亡风险。该合作研究项目--与Highland Biosciences Limited(HBL)、NIHR London体外诊断合作社(LIVDC)、帝国理工学院NHS信托基金、苏塞克斯大学和苏塞克斯大学医院NHS基金会信托基金--将开发新的生物传感器产品技术。这种新设备将在几分钟内将患者的凝血状态结果送到患者的床边，从而指导创伤患者选择最佳治疗和管理方案，并减少除受影响最严重的患者以外的所有患者的输血需求和输血次数。

Traumatic injuries are a major unmet clinical need and the leading cause of death and disability among young people around the world. Trauma treatment and management is very complex, costly and resource-intense. It is a fast-moving environment where clinicians constantly seek the best treatment to manage and stabilise very sick patients. In these patients, blood loss causes usual levels of clotting factors to be deranged leading to coagulopathy. This defective clotting processes results in continued uncontrolled bleeding which has a high risk of mortality. This collaborative research project -- with Highland Biosciences Limited (HBL), the NIHR London In-Vitro Diagnostic Co-operative (LIVDC), Imperial College Healthcare NHS Trust, University of Sussex and University Hospitals Sussex NHS Foundation Trust - will develop new biosensor product technology. The new device will guide the selection of the best treatment and management regime for trauma patients by bringing results of a patient's clotting status to the patient's bedside within a few minutes and reduce the need for and number of blood transfusions in all but the most severely affected patients.